 EZN-2208 will be administered by i.v. infusion weekly for 3 weeks in 4-week cycles. The cetuximab infusion will be administered before the EZN-2208 Arm B or irinotecan Arm C infusion. Study treatment will be continued until evidence of disease progression, unacceptable toxicity, or withdrawal of the patients consent for participation in the study. 